The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
The vaccine is under FDA review
Medicines, including insulin, to be available in 40 lower-income countries
The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.
The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
Prior to this, Maria held multiple roles at Novartis including Head of Global Manufacturing Functions, and Global Head of Manufacturing, Science & Technology
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
Subscribe To Our Newsletter & Stay Updated
